Average Wholesale Price (AWP) Pharmaceutical Litigation
Goldenberg Schneider is co-counsel with Hagens Berman Sobol Shapiro challenging pharmaceutical companies’ practice of charging for drugs based on average wholesale price (AWP). This massive multidistrict litigation focuses on a group of physician-administered drugs that are used to treat many types of cancer and other serious illnesses. Plaintiffs allege in the complaint that the pharmaceutical companies consistently inflated the prices of these prescription drugs as part of a scheme to overcharge consumers. Goldenberg Schneider also assisted the Connecticut Attorney General’s office in its successful cost recoupment litigation against many of the same pharmaceutical companies related to this same pricing scheme.